Glucagon-like peptide-1 receptor agonists and pancreatic outcomes in chronic pancreatitis: a real-world cohort study.

Authors

Arkadeep Dhali, Rick Maity, Fayaz Khan, Jyotirmoy Biswas, Abdul Rafae Faisal

Published in

BMC gastroenterology. Jul 16, 2026. Epub Jul 16, 2026.

Abstract

To evaluate the association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy and pancreatic, gastrointestinal, and mortality outcomes in chronic pancreatitis (CP) using the TriNetX US Collaborative Network.
CP patients face heightened risks of pancreatic insufficiency, cancer, and mortality. There are concerns regarding GLP-1 RA use and adverse pancreatic outcomes.
In this retrospective cohort study, adults (age ≥ 18 years) with CP (ICD-10-CM K86.0 or K86.1) were stratified into Cohort 1 (CP + GLP-1 RA, n = 10,978) and Cohort 2 (CP without GLP-1 RA, n = 245,024. After propensity score matching on age, sex, race, and comorbidities, 10,625 patients remained in each cohort. Primary and secondary outcomes were assessed over 3 years via risk analyses and Kaplan-Meier survival analyses.
GLP-1 RA users had significantly lower incidence of exocrine insufficiency (3.1% vs. 6.3%; RR 0.491, 95%CI 0.429-0.562, p < 0.001), endocrine insufficiency (6.0% vs. 8.2%; RR 0.742, 95%CI 0.664-0.829, p < 0.001), recurrent acute pancreatitis (5.8% vs. 10.5%; RR 0.554, 95%CI 0.487-0.631, p < 0.001), pancreatic cancer (2.0% vs. 3.9%; RR 0.498, 95%CI 0.421-0.590, p < 0.001), ED visits (17.4% vs. 22.4%; RR 0.778, p < 0.001), hospitalizations (18.0% vs. 26.3%; RR 0.684, p < 0.001), and gastroparesis (2.3% vs. 3.0%; RR 0.771, p = 0.003). Critically, all-cause mortality was 6.9% in GLP-1 RA users versus 16.4% in non-users (RR 0.423, 95%CI 0.390-0.459, p < 0.001), with 3-year survival of 88.6% versus 79.1%.
GLP-1 RA use was associated with substantially lower risks of pancreatic and gastrointestinal outcomes, along with improved overall survival, providing observational evidence supporting safety signals.

PMID:
42458277
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.